Insmed Beats Stock-Drop Suit Over Lung Disease Drug

By Jeannie O'Sullivan · February 16, 2018, 8:50 PM EST

A New Jersey federal judge on Thursday tossed a proposed class action alleging that Insmed Inc. misled investors over the likelihood that a lung disease drug would gain market approval in...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

HOEY v. INSMED INCORPORATED et al

Case Number

Court

New Jersey

Nature of Suit

Securities/Commodities

Date Filed

July 15, 2016

Recent Articles By Jeannie

December 13, 2023
Pa. Justices Will Review Order Allowing Hospital Closure
April 13, 2022
Nursing Home Workers' Insurance Scam Claims Survive
April 06, 2022
Titan Of The Plaintiffs Bar: Joseph Saveri's Steven Williams
April 05, 2022
Valsartan MDL Judge OKs Out-Of-State Litigants, More Claims
March 31, 2022
Health Plans Squeezed By Opioid Drug Scheme, 3rd Circ. Told
March 16, 2022
Virus Whistleblower Suit Short On Specifics, NJ Officials Say
March 10, 2022
NJ Court Must Rethink Archer DQ In Dental Office Biz Dispute
March 04, 2022
Fact Disputes Keep Cardiac Hospital's ER Contract Row Alive
February 28, 2022
3rd Circ. Preview: March Roars With Ch. 11, Poaching Spats
February 22, 2022
Charities Ensnared In NJ Antitrust Suit Over Cancer Drugs